$IBN

Indian stock markets fell for a second day, with the Sensex down 539 points (0.7%) and Nifty down 117 points (0.48%) due to geopolitical uncertainty and last-minute selling in blue-chip stocks like HDFC Bank and Reliance Industries. HDFC Bank dropped 2.08% after a US lawsuit, while Reliance Industries fell 1%. Brent crude rose 0.67% to $88.43 per barrel. Analysts cited expiry volatility and Middle East tensions as factors.

Goldman Sachs has identified six Indian banks with 'Buy' ratings, expecting 18%-37% upside. ICICI Bank (highest at 37%) and Kotak Mahindra Bank (31%) are top picks, with HDFC Bank, Axis Bank, Federal Bank, and AU Small Finance Bank also recommended. The brokerage anticipates improving loan growth, stable margins, and stronger operating leverage to boost profitability.

Bernstein sees upside in select Indian banks, with HDFC Bank (56.7%), ICICI Bank (31.1%), Kotak Mahindra Bank (32.4%), and Axis Bank (14.8%) showing potential. SBI has modest upside (2.6%), while IndusInd Bank may decline. The report cites strong loan growth, easing margin pressure, and stable asset quality as key drivers.

ICICI Bank's shares fell on August 24, 2026, despite a 15.9% net profit growth in Q1. The bank plans to raise $5 billion in overseas borrowings, using RBI's swap facility. Investors monitor global interest rates, currency volatility, and the upcoming FCNR-B deposit swap window closure.

ICICI Bank (ICICIBANK) shares rose 0.26% to ₹1,423.70 on August 24, 2026, after Goldman Sachs initiated a 'Buy' rating, citing sector recovery and private bank outperformance. The bank also issued $750 million in notes, boosting investor confidence. Broader sector tailwinds and projected profit growth support the positive outlook.

Indian stocks may see activity due to company updates. Indian Oil signed a fuel deal with Mauritius, Zee Entertainment issued warrants, and Welspun Corp won a Rs 17,200 crore order. HDFC Bank raised $1.75B, ICICI Bank doubled its borrowing limit, and Zydus Lifesciences got USFDA approval for a generic drug. Jubilant Pharmova received USFDA approval for a US facility, and JSW Infrastructure plans to acquire JSW Overseas. Accel entities sold a 5% stake in Amagi Media Labs.

ICICI Bank issued $750M in senior unsecured notes under its $7.5B GMTN program. The notes received BBB (S&P) and Baa3 (Moody's) ratings and will be listed on international exchanges. ICICI Bank's shares traded at Rs. 1419.00 on BSE, up from Rs. 1411.50.

ICICI Bank's board approved a $5 billion limit for overseas borrowing via bonds, notes, and offshore CDs. The bank has already raised $1.7 billion under RBI's swap facility. This move is part of a trend of Indian banks accessing global markets for funding.

ICICI Bank's board approved a USD 5 billion offshore borrowing limit, doubling its previous USD 2.5 billion cap. The bank has already raised USD 2.05 billion in debt this month, with Q1 FY27 net profit up 15.95% YoY. The move aims to secure low-cost capital ahead of RBI's swap window closure.

ICICI Bank's Q1FY27 profit after tax rose 15.9% YoY to ₹148.05 billion. Advances grew 19.6% YoY to ₹16,312.60 billion. The board approved a ₹12 per share dividend for FY26. The bank's CET-1 ratio was 16.19% at Q1FY27. Deposit growth was 14.0% YoY, while advances grew 19.6% YoY, indicating aggressive credit expansion.